Brought to you by 
TerSera pays $250mm up front for US/Canadian rights to AZ's Zoladex
21 Feb 2017
Executive Summary
AstraZeneca PLC granted specialty pharma start-up TerSera Therapeutics LLC exclusive US and Canadian marketing rights to its cancer product Zoladex (goserelin). AZ retains rights in the rest of the world, and will manufacture and supply the drug to TerSera.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TerSera pays $250mm up front for US/Canadian rights to AZ's Zoladex
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice